227 related articles for article (PubMed ID: 24855645)
1. Targeting spare CC chemokine receptor 5 (CCR5) as a principle to inhibit HIV-1 entry.
Jin J; Colin P; Staropoli I; Lima-Fernandes E; Ferret C; Demir A; Rogée S; Hartley O; Randriamampita C; Scott MG; Marullo S; Sauvonnet N; Arenzana-Seisdedos F; Lagane B; Brelot A
J Biol Chem; 2014 Jul; 289(27):19042-52. PubMed ID: 24855645
[TBL] [Abstract][Full Text] [Related]
2. Multifaceted mechanisms of HIV inhibition and resistance to CCR5 inhibitors PSC-RANTES and Maraviroc.
Lobritz MA; Ratcliff AN; Marozsan AJ; Dudley DM; Tilton JC; Arts EJ
Antimicrob Agents Chemother; 2013 Jun; 57(6):2640-50. PubMed ID: 23529732
[TBL] [Abstract][Full Text] [Related]
3. Two mechanisms for human immunodeficiency virus type 1 inhibition by N-terminal modifications of RANTES.
Pastore C; Picchio GR; Galimi F; Fish R; Hartley O; Offord RE; Mosier DE
Antimicrob Agents Chemother; 2003 Feb; 47(2):509-17. PubMed ID: 12543651
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 exploits CCR5 conformational heterogeneity to escape inhibition by chemokines.
Colin P; Bénureau Y; Staropoli I; Wang Y; Gonzalez N; Alcami J; Hartley O; Brelot A; Arenzana-Seisdedos F; Lagane B
Proc Natl Acad Sci U S A; 2013 Jun; 110(23):9475-80. PubMed ID: 23696662
[TBL] [Abstract][Full Text] [Related]
5. The LD78beta isoform of MIP-1alpha is the most potent CC-chemokine in inhibiting CCR5-dependent human immunodeficiency virus type 1 replication in human macrophages.
Aquaro S; Menten P; Struyf S; Proost P; Van Damme J; De Clercq E; Schols D
J Virol; 2001 May; 75(9):4402-6. PubMed ID: 11287590
[TBL] [Abstract][Full Text] [Related]
6. PSC-RANTES blocks R5 human immunodeficiency virus infection of Langerhans cells isolated from individuals with a variety of CCR5 diplotypes.
Kawamura T; Bruse SE; Abraha A; Sugaya M; Hartley O; Offord RE; Arts EJ; Zimmerman PA; Blauvelt A
J Virol; 2004 Jul; 78(14):7602-9. PubMed ID: 15220435
[TBL] [Abstract][Full Text] [Related]
7. Arrestin Recruitment to C-C Chemokine Receptor 5: Potent C-C Chemokine Ligand 5 Analogs Reveal Differences in Dependence on Receptor Phosphorylation and Isoform-Specific Recruitment Bias.
Martins E; Brodier H; Rossitto-Borlat I; Ilgaz I; Villard M; Hartley O
Mol Pharmacol; 2020 Nov; 98(5):599-611. PubMed ID: 32943494
[TBL] [Abstract][Full Text] [Related]
8. Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity.
Mack M; Luckow B; Nelson PJ; Cihak J; Simmons G; Clapham PR; Signoret N; Marsh M; Stangassinger M; Borlat F; Wells TN; Schlöndorff D; Proudfoot AE
J Exp Med; 1998 Apr; 187(8):1215-24. PubMed ID: 9547333
[TBL] [Abstract][Full Text] [Related]
9. Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs.
Torre VS; Marozsan AJ; Albright JL; Collins KR; Hartley O; Offord RE; Quiñones-Mateu ME; Arts EJ
J Virol; 2000 May; 74(10):4868-76. PubMed ID: 10775626
[TBL] [Abstract][Full Text] [Related]
10. Agonist-induced internalization of CC chemokine receptor 5 as a mechanism to inhibit HIV replication.
Ferain T; Hoveyda H; Ooms F; Schols D; Bernard J; Fraser G
J Pharmacol Exp Ther; 2011 Jun; 337(3):655-62. PubMed ID: 21389095
[TBL] [Abstract][Full Text] [Related]
11. G protein subtype-specific signaling bias in a series of CCR5 chemokine analogs.
Lorenzen E; Ceraudo E; Berchiche YA; Rico CA; Fürstenberg A; Sakmar TP; Huber T
Sci Signal; 2018 Oct; 11(552):. PubMed ID: 30327411
[TBL] [Abstract][Full Text] [Related]
12. LD78beta, a non-allelic variant of human MIP-1alpha (LD78alpha), has enhanced receptor interactions and potent HIV suppressive activity.
Nibbs RJ; Yang J; Landau NR; Mao JH; Graham GJ
J Biol Chem; 1999 Jun; 274(25):17478-83. PubMed ID: 10364178
[TBL] [Abstract][Full Text] [Related]
13. CC chemokine receptor 5 (CCR5) desensitization: cycling receptors accumulate in the trans-Golgi network.
Escola JM; Kuenzi G; Gaertner H; Foti M; Hartley O
J Biol Chem; 2010 Dec; 285(53):41772-80. PubMed ID: 21041313
[TBL] [Abstract][Full Text] [Related]
14. Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants.
Mosier DE; Picchio GR; Gulizia RJ; Sabbe R; Poignard P; Picard L; Offord RE; Thompson DA; Wilken J
J Virol; 1999 May; 73(5):3544-50. PubMed ID: 10196243
[TBL] [Abstract][Full Text] [Related]
15. Beta-arrestin binding to CC chemokine receptor 5 requires multiple C-terminal receptor phosphorylation sites and involves a conserved Asp-Arg-Tyr sequence motif.
Huttenrauch F; Nitzki A; Lin FT; Höning S; Oppermann M
J Biol Chem; 2002 Aug; 277(34):30769-77. PubMed ID: 12065593
[TBL] [Abstract][Full Text] [Related]
16. Highly potent, fully recombinant anti-HIV chemokines: reengineering a low-cost microbicide.
Gaertner H; Cerini F; Escola JM; Kuenzi G; Melotti A; Offord R; Rossitto-Borlat I; Nedellec R; Salkowitz J; Gorochov G; Mosier D; Hartley O
Proc Natl Acad Sci U S A; 2008 Nov; 105(46):17706-11. PubMed ID: 19004761
[TBL] [Abstract][Full Text] [Related]
17. Genetic subtype-independent inhibition of human immunodeficiency virus type 1 replication by CC and CXC chemokines.
Trkola A; Paxton WA; Monard SP; Hoxie JA; Siani MA; Thompson DA; Wu L; Mackay CR; Horuk R; Moore JP
J Virol; 1998 Jan; 72(1):396-404. PubMed ID: 9420238
[TBL] [Abstract][Full Text] [Related]
18. Mutation of the DRY motif reveals different structural requirements for the CC chemokine receptor 5-mediated signaling and receptor endocytosis.
Lagane B; Ballet S; Planchenault T; Balabanian K; Le Poul E; Blanpain C; Percherancier Y; Staropoli I; Vassart G; Oppermann M; Parmentier M; Bachelerie F
Mol Pharmacol; 2005 Jun; 67(6):1966-76. PubMed ID: 15761117
[TBL] [Abstract][Full Text] [Related]
19. Human immunodeficiency virus type 1 entry inhibitors selected on living cells from a library of phage chemokines.
Hartley O; Dorgham K; Perez-Bercoff D; Cerini F; Heimann A; Gaertner H; Offord RE; Pancino G; Debré P; Gorochov G
J Virol; 2003 Jun; 77(12):6637-44. PubMed ID: 12767983
[TBL] [Abstract][Full Text] [Related]
20. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140.
Trkola A; Ketas TJ; Nagashima KA; Zhao L; Cilliers T; Morris L; Moore JP; Maddon PJ; Olson WC
J Virol; 2001 Jan; 75(2):579-88. PubMed ID: 11134270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
